2022年5月13日，国自然基金委发布了《2022年查处的科研不端案件处理决定（第一批次）》，将其中给予通报批评的10份处理决定（网络发布版）予以公布。此次10份处理决定涉及10所高校，共计14人。涉事高校包括211高校—天津医科大学、以及浙江大学、天津大学、西安交通大学、上海交通大学、大连理工大学这5所985高校。
国自然基金委对汤华共通报了32篇文章，其中截至2022年5月16日，已经被撤稿10篇文章（点击阅读）。撤销汤华国家自然科学基金项目“Hsa-miR-10a抑制结肠癌转移的分子机制研究”（批准号30873017）、“在卵巢癌细胞中miRNA与TNF-α-IKK-NF-κB信号途径基因的相互调控作用研究”（批准号91029714）、“miR-372调控宫颈癌细胞周期的机制研究”（批准号31071191）、“PSMC3对Ago2稳定性的调节及其机制研究”（批准号31270818）、“肝癌细胞中miR-615-5p的表观遗传调控及功能机制研究”（批准号81572790）、“炎性因子激活NF-κB/STAT3通过表观遗传修饰调控肿瘤细胞恶性行为及前转移微环境形成的机制研究”（批准号91629302）、“HPVE6/E7调控METTL3所介导的m6A-RNA在宫颈癌细胞中的作用与机制研究”（批准号81830094），追回上述7个项目已拨资金，取消汤华国家自然科学基金项目申请资格5年（2022年1月18日至2027年1月17日），给予汤华通报批评。
关于对汤华等发表的论文存在图片不当操作及实验数据混乱以及项目申请书、进展报告及结题报告中存在虚假信息等问题的处理决定
国科金监处〔2022〕2号
国家自然科学基金委员会监督委员会对天津医科大学汤华等发表的论文涉嫌学术不端开展了调查，涉事论文如下：
论文1: “Yaqi Hu#, Xu Guo#, Jinxia Wang#, Yankun Liu, Huijie Gao, Hongxia Fan, Xiangyang Nong, Xi Yang, Min Liu, Shengping Li, Hua Tang*. A novel microRNA identified in hepatocellular carcinomas is responsive to LEF1 and facilitates proliferation and epithelial-mesenchymal transition via targeting of NFIX. Oncogenesis. 2018, 7(2):22.”（标注基金号91629302、81572790、31270818、81602410）（已被撤稿）
论文2: “Xi Yang, Yaqi Hu, Yankun Liu, Weiying Liu, Xiaoqing Zhao, Min Liu, Hua Tang*. C14orf28 downregulated by miR-519d contributes to oncogenicity and regulates apoptosis and EMT in colorectal cancer. Molecular and Cellular Biochemistry. 2017, 434(1-2):197-208.” (标注基金号81572790、91629302、91029714、31270818)
论文3: “Weiying Liu, Shixing Wang, Qi Sun, Zhen Yang, Min Liu, Hua Tang*. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer. International Journal of Cancer. 2018, 142(10):2068-2079.”（标注基金号81602512、91629302、81572790、31270818、91029714）（已被撤稿）
论文4: “Peipei Zhang#, Xiangling Wang#, Wei Zhao#, Bing Qi, Qian Yang, Haiying Wan, Zeyu Shuang, Min Liu, Xin Li, Shengping Li*, Hua Tang*. DNA methylation-mediated repression of miR-941 enhances lysine (K)-specific demethylase 6B expression in hepatoma cells.The Journal of Biological Chemistry.2014. 289(35):24724-35.” (标注基金号31270818、91029714、31071191)
论文5: “Xue Liu#, Qian Liu#, Yajie Fan#, Shaohua Wang#, Xinrui Liu, Lihua Zhu, Min Liu, Hua Tang*. Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells. FEBS Letters. 2014, 588(17):3160-3169.” (标注基金号91029714、31270818、31101000)
论文6: “Liming Guo#, Rui Gao#, Jianchen Gan#, Yanan Zhu, Junyi Ma, Ping Lv, Yi Zhang, Shengping Li, Hua Tang*. Downregulation of TNFRSF19 and RAB43 by a novel miRNA, miR-HCC3, promotes proliferation and epithelial–mesenchymal transition in hepatocellular carcinoma cells.Biochemical and Biophysical Research Communications. 2020, 525(2):425-432.” (标注基金号81830094、91629302、81572790、31270818)
论文7：“Lili Yao#, Yadi Zhou#, Zhenhua Sui#, YanlingZhang, Yankun Liu, Hong Xie, Huijie Gao, Hongxia Fan, Yi Zhang, Min Liu, Shengping Li, Hua Tang*. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine.2019, 48:117-129.” (标注基金号 81830094、91629302、31270818)（已被撤稿）
论文8: “Xiaoxiao Kong#, YanruLv#, Liping Shao#, Xiangyang Nong, Guangling Zhang, Yi Zhang, Hongxia Fan, Min Liu, Xin Li, Hua Tang*. HBX-induced MiR-1269b in NF-κB dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. J Transl Med.2016, 14(1):189.” (标注基金号 91029714、81201281、31270818、81572790)
论文9: “Zheng Chen#, Xiangling Wang#, Ruiyan Liu#, Lin Chen, Jianying Yi, Bing Qi, Zeyu Shuang, Min Liu, Xin Li, Shengping Li, Hua Tang*. KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells. Oncotarget. 2017, 8(11):17712-17725.” (标注基金号31270818、91029714、81371667、81572790)
论文10: “Qian Liu#, Xu Guo#, Shengshun Que#, Xi Yang, Hongxia Fan, Min Liu, Xin Li, Hua Tang*. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget. 2017, 8(27):43768-43781.” (标注基金号91029714、81572790、31270818、31101000)
论文11: “Lifen Wu#, Chunli Cai#, Xinghua Wang#, Min Liu, Xin Li, Hua Tang*. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Letters. 2011, 585(9):1322-1330.” (标注基金号30873017、91029714、31071191)（表达关注）
论文12: “Xuemei Xu#, Xiaobo Wang#, Miaomiao Chen#, Tao Liu, Yixuan Li, Weihua Jia, Min Liu, Xin Li, Hua Tang*. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Letters. 2012, 322(2):148-158.” (标注基金号30873017、91029714、31071191)（已被撤稿）
论文13: “Ruiqing Peng#, Haiying Wan#, Haifang Li#, Min Liu, Xin Li, Hua Tang*. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. The Journal of Biological Chemistry. 2012, 287(17): 14301–14309.” (标注基金号30873017、91029714、31071191)
论文14: “Jinghua Wang#, Le Zhang#, Yuwei Ma#, Jing Xiao, Yi Zhang, Min Liu, Hua Tang*. MicroRNA-34a-upregulated retinoic acid-inducible gene-I promotes apoptosis and delays cell cycle transition in cervical cancer cells .DNA and cell biology. 2016, 35(6): 267-279.” (标注基金号 31301132、91029714、31270818、31071191)（已被撤稿）
论文15：“Lan Li#, Li He#, Jianli Zhao#, Jing Xiao, Min Liu, Xin Li, Hua Tang*. MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines. J Cell Biochem. 2015, 116(6):1050-9.”（标注基金号31270818、91029714、31071191）（已被撤稿）
论文16：“Jianli Zhao#, Le Zhang#, Xu Guo#, Jinghua Wang, Wen Zhou, Min Liu, Xin Li, Hua Tang*. miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymaltransition in cervical cancer cells. IUBMB Life. 2015, 67(5):380-94.”（标注基金号31270818、91029714、31071191、31101000、81201281）
论文17：“Jing Ru#, Huahui Sun#, Hongxia Fan#, Chunmei Wang, Yixuan Li, Min Liu, Hua Tang*. MiR-23a Facilitates the Replication of HSV-1 through the Suppression of Interferon Regulatory Factor 1.Plos One. 2014, 9(12):e114021.”（标注基金号31100933、31270818、91029714、31071191、81201281）
论文18：“Zhen Yang#, Xiangling Wang#, Ru Bai#, Weiying Liu, Xin Li, Min Liu, Hua Tang*. miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells. British Journal of Cancer. 2016, 115:731–740.”（标注基金号91029714、31270818、81572790）
论文19：“Xue Liu#, Jing Ru#, Jian Zhang#, Lihua Zhu, Min Liu, Xin Li, Hua Tang*. miR-23a Targets Interferon Regulatory Factor 1 and Modulates Cellular Proliferation and Paclitaxel-Induced Apoptosis in Gastric Adenocarcinoma Cells. Plos One. 2013, 8(6): e64707.”（标注基金号31270818、91029714、31071191）（已被撤稿）
论文20：“Mingxue Zhang#, Jie Zhang#, Hong Zhang*, Hua Tang*. miR-24-3p suppresses malignant behavior of lacrimal adenoid cystic carcinoma by targeting prkch to regulate p53/p21 pathway. Plos One, 2016, 11 (6):e0158433.”（标注基金号91029714、31270818、81572790）（已被撤稿）
论文21：“Hua Li#, Hui Song#, Xiaoyong Yuan, Jun Li, Hua Tang*. miR-30a reverses TGF-β2-induced migration and EMT in posterior capsular opacification by targeting Smad2. Mol Biol Rep. 2019, 46(4):3899-3907.” （标注基金号91629302、81572790）
论文22：“Junfei Guo, Jing Lv, Min Liu, Hua Tang*. miR-346 up-regulates argonaute 2 (ago2) protein expression to augment the activity of other microRNAs (miRNAs) and contributes to cervical cancer cell malignancy. J Biol Chem. 2015, 290(51): 30342–30350.” （标注基金号31270818、91029714、31071191）
论文23：“Weiying Liu, Zhen Yang, Qi Sun, Xi Yang, Yang Hu, Hong Xie, Huijie Gao, Liming Guo, Jianying Yi, Min Liu, Hua Tang*. miR-377-3p drives malignancy characteristics via upregulating GSK-3β expression and activating NF-κB pathway in hCRC cells. Journal of Cellular Biochemistry. 2018, 119(2):2124-2134.”（标注基金号81602512、91629302、81572790、31270818、91029714）（表达关注）
论文24：“Yang Hu, Hong Xie, Yankun Liu, Weiying Liu, Min Liu, Hua Tang*. miR-484 suppresses proliferation and epithelial- mesenchymal transition by targeting of ZEB1 and SMAD2 in cervical cancer cells. Cancer Cell International. 2017,17(1): 36.”（标注基金号91029714、31270818、81572790）（已被撤稿）
论文25：“Lingyun Zhang, Min Liu*, Xin Li, Hua Tang*. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 2013, 288(6):4035–4047.”（标注基金号31270818、91029714、31071191）
论文26：“Jing Xiao#, Yankun Liu#, Fuxia Wu#, Ruiyan Liu#, YongliXie, Qian Yang, Yufeng Li, Min Liu, Shengping Li, Hua Tang*. miR-639 expression is silenced by dnmt3a-mediated hypermethylation and functions as a tumor suppressor in liver cancer cells. Molecular Therapy. 2020, 28(2):587-598.”（标注基金号81830094、81572790、91629302、81573115）（已被撤稿）
论文27：“Jian Zhang#, Haidong Wu#, Pu Li#, Yanzheng Zhao, Min Liu, Hua Tang*. NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells. Journal of Translational Medicine. 2014, 12:155.”（标注基金号31270818、91029714、31071191、31101000）
论文28：“Chang Su#, Zhongjie Ren#, Fang Wang, Min Liu, Xin Li, Hua Tang*. PIWIL4 regulates cervical cancer cell line growth and is involved in down-regulating the expression of p14ARF and p53. FEBS Letters. 2012, 586:1356–1362.”（标注基金号91029714、31071191）
论文29：“Ying Zhu#, Yan Zhang#, Zhenhua Sui, Yi Zhang, Min Liu, Hua Tang*. USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells. Oncotarget. 2017,8(30):48725-48736.”（标注基金号91029714; 31270818: 81572790）
论文30：“Chaoqun Ma#, Ying Qi#, Liping Shao#, Min Liu, Xin Li, Hua Tang*. Downregulation of miR-7 upregulates Cullin 5 (CUL5) to facilitate G1/S transition in human hepatocellular carcinoma cells. IUBMB Life, 2013. 65(12): 1026-34.”（标注基金号91029714、31071191、31270818）
论文31：“Qi Sun#, Zhen Yang#, Pu Li#, Xu Wang, Lu Sun, Shixing Wang, Min Liu, Hua Tang*. A novel miRNA identified in GRSF1 complex drives the metastasis via the PIK3R3/AKT/NF-κB and TIMP3/MMP9 pathways in cervical cancer cells. Cell Death and Disease.2019,10:636.”（标注基金号91629302、81572790、81830094、31270818）
论文32：“Yankun Liu, Yingnan Zhang, Haidong Wu, Yufeng Li, Yi Zhang, Min Liu, Xin Li, Hua Tang*. miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis. Cell Death &Disease. 2017; 8(4): e2739.” （标注基金号91629302、31270818、91029714、81572790、30873017）
经依托单位调查，上述论文存在图片不当操作及实验数据混乱等问题，通讯作者汤华对上述问题负主要责任。此外，汤华将上述论文多次列入其7项国家自然科学基金项目（批准号30873017、91029714、31071191、31270818、81572790、91629302、81830094）申请书、进展报告、结题报告中，还应对在项目申请书、进展报告或结题报告中存在虚假信息的客观结果负责。
经国家自然科学基金委员会监督委员会五届十二次会议（生命医学专业委员会）审议、国家自然科学基金委员会2022年第2次委务会议审定，决定依照《国家自然科学基金条例》第三十五条第四项、《国家自然科学基金委员会监督委员会对科学基金资助工作中不端行为的处理办法（试行）》第十六条第二项、第十七条第三项，撤销汤华国家自然科学基金项目“Hsa-miR-10a抑制结肠癌转移的分子机制研究”（批准号30873017）、“在卵巢癌细胞中miRNA与TNF-α-IKK-NF-κB信号途径基因的相互调控作用研究”（批准号91029714）、“miR-372调控宫颈癌细胞周期的机制研究”（批准号31071191）、“PSMC3对Ago2稳定性的调节及其机制研究”（批准号31270818）、“肝癌细胞中miR-615-5p的表观遗传调控及功能机制研究”（批准号81572790）、“炎性因子激活NF-κB/STAT3通过表观遗传修饰调控肿瘤细胞恶性行为及前转移微环境形成的机制研究”（批准号91629302）、“HPVE6/E7调控METTL3所介导的m6A-RNA在宫颈癌细胞中的作用与机制研究”（批准号81830094），追回上述7个项目已拨资金，取消汤华国家自然科学基金项目申请资格5年（2022年1月18日至2027年1月17日），给予汤华通报批评。